Search results for "25"

showing 10 items of 3263 documents

„Das Leben ist nur ein Spiegel“ – Schopenhauers kritischer Lebensbegriff

2012

Schopenhauer gilt als Vorreiter oder erster Vertreter der Lebensphilosophie, wie sie später von Dilthey, Nietzsche, Bergson und anderen entfaltet wurde. Im Unterschied zur klassischen Lebensphilosophie und zu den an sie anknüpfenden ethischen Entwürfen wird das Leben bei Schopenhauer aber nicht als Zweck betrachtet, sondern als Mittel zu einem anderen Zweck, nämlich für die Ethik, die in der Verneinung des Willens zum Leben gipfelt. Schon in den frühesten handschriftlichen Aufzeichnungen verwendet Schopenhauer verschiedene Metaphern, um das Leben als Medium der ethischen Erkenntnis zu charakterisieren. Besonders häufig tritt dabei das Bild vom Leben als Spiegel auf, in dem der Mensch sein e…

lcsh:Ethicslcsh:Philosophy (General)lcsh:Blcsh:Philosophy. Psychology. Religionlcsh:B1-5802lcsh:BJ1-1725ethic@ - An international Journal for Moral Philosophy
researchProduct

Flujos de transporte y relaciones interurbanas en la provincia de Valencia.

1987

Julia Salom Carrasco: Julia.Salom@uv.es Este artículo recoge parte de los resultados dcl proyecto dc investigación <‘Jerarquía urbana y áreas de atracción en la provincia de Valencia’, subvencionado por el Instituto de Geografía de la Institución Alfonso cl Magnánimo dc la Diputación Provincial de Valencia. Agradecemos la colaboración de A. Andrés Gomis, J. R. cuevas Camps y M. Montero Fernández, que recopilaron y tabularon la información, y realizaron gran parle de la cartografía.

lcsh:HT165.5-169.9Geografíalcsh:Cities. Urban geographylcsh:GF125UNESCO::GEOGRAFÍA::Geografía regionallcsh:G1-922Valencia:GEOGRAFÍA::Geografía regional [UNESCO]Geografía; Urbanismo; Valencialcsh:City planninglcsh:Geography (General)Urbanismo
researchProduct

NPM-ALK-reactive T-cell responses in children and adolescents with NPM-ALK positive anaplastic large cell lymphoma

2019

ABSTRACT The oncoantigen nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) induces cellular and humoral immune responses in patients with NPM-ALK-positive anaplastic large cell lymphoma (ALCL). We characterize the NPM-ALK-specific T-cell responses in a cohort of pediatric and adolescent ALCL-patients in remission without Human Leucocyte Antigen (HLA)-preselection. First, we assessed NPM-ALK-reactive T-cell responses and their HLA-class I restriction in patients by using dendritic cells (DCs) transfected with in vitro transcribed (IVT) NPM-ALK-RNA for CD8 (n = 20) or CD3 (n = 9) T-cell stimulation. NPM-ALK-specific T-cells were detected in twelve of 29 patients (nine of 20 with CD8-selected…

lcsh:Immunologic diseases. Allergy0301 basic medicineALK-Positive Anaplastic Large Cell LymphomaT cellImmunologylcsh:RC254-282IFN-γ ELISPOT03 medical and health sciences0302 clinical medicineImmune systemimmune system diseaseshemic and lymphatic diseasesmedicineImmunology and AllergyIn patientNPM-ALKImmune responseAnaplastic large-cell lymphomaOriginal Researchintegumentary systemKinasebusiness.industryT-cellslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseALCL3. Good healthLymphomaOncoantigen030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisCancer researchlcsh:RC581-607businessOncoImmunology
researchProduct

Reciprocal influence of B cells and tumor macro and microenvironments in the ApcMin/+ model of colorectal cancer

2017

One of the most fascinating aspects of the immune system is its dynamism, meant as the ability to change and readapt according to the organism needs. Following an insult, we assist to the spontaneous organization of different immune cells which cooperate, locally and at distance, to build up an appropriate response. Throughout tumor progression, adaptations within the systemic tumor environment, or macroenvironment, result in the promotion of tumor growth, tumor invasion and metastasis to distal organs, but also to dramatic changes in the activity and composition of the immune system. In this work, we show the changes of the B-cell arm of the immune system following tumor progression in the…

lcsh:Immunologic diseases. Allergy0301 basic medicineColorectal cancerImmunologySpleenintestinal cancerBiologylcsh:RC254-282Metastasis03 medical and health sciencesImmune systemPeritoneummedicineImmunology and Allergyapcmin/+ miceApcMin/+mice; B lymphocytes; IgA; IL-10; intestinal cancer; Immunology and Allergy; Immunology; OncologyB lymphocyteApcMin/+micelcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasePhenotypeInterleukin 10030104 developmental biologymedicine.anatomical_structureOncologyTumor progressionIL-10Immunologyb lymphocyteslcsh:RC581-607IgAOncoImmunology
researchProduct

Tumor lymphocyte immune response to preoperative radiotherapy in locally advanced rectal cancer: The LYMPHOREC study

2017

IF 7.719; International audience; Introduction: Some studies have suggested that baseline tumor-infiltrating-lymphocytes (TILs), such as CD8+ and FoxP3+ T-cells, may be associated with a better prognosis in colorectal cancer. We sought to investigate modulation of the immune response by preoperative radiotherapy (preopRT) and its impact on survival in locally advanced rectal cancer (LARC). Materials & Methods: We analyzed data for 237 patients with LARC who received RT. Density of TILS (CD8+ and FoxP3+) in intraepithelial (iTILs) and stromal compartments (sTILs) were evaluated from surgery pathological specimens and biopsies performed at baseline. The primary endpoint was to assess the impa…

lcsh:Immunologic diseases. Allergy0301 basic medicineOncologymedicine.medical_specialtyColorectal cancermedicine.medical_treatmentImmunology[SDV.CAN]Life Sciences [q-bio]/Cancerchemical and pharmacologic phenomenalcsh:RC254-282radiation therapy[ SDV.CAN ] Life Sciences [q-bio]/Cancer03 medical and health sciences0302 clinical medicineInternal medicinemedicineClinical endpointImmunology and Allergyrectal cancertranslational studyOriginal ResearchUnivariate analysisbusiness.industryTumor-infiltrating lymphocytesDose fractionationFOXP3hemic and immune systemslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.disease3. Good healthRadiation therapy030104 developmental biologyOncology030220 oncology & carcinogenesistumor-infiltrating lymphocyteslcsh:RC581-607businessAdjuvant
researchProduct

The prognostic and predictive value of IKZF1 and IKZF3 expression in T-cells in patients with multiple myeloma

2018

Purpose: While recent studies described the role of IKZF1/3 proteins in multiple myeloma (MM) cells, few have highlighted the significance of IKZF1/3 expression in T-cells. In this study we examine the prognostic and predictive value of IKZF1/3 expression in T-cells in patients with MM stage III. Experimental design: We analysed the IKZF1/3 expression levels in T-cells from 45 MM stage I (MMI) and 50 newly diagnosed MM stage III (MMIII) patients, according to Durie-Salmon staging system, by flow cytometry to examine their prognostic and predictive value. We also combined in vivo observations with in vitro assays to determine the effect of IKZF1/3 expression on the T-cell immunophenotype and…

lcsh:Immunologic diseases. Allergy0301 basic medicineOncologymedicine.medical_specialtyImmunologyMedizinlcsh:RC254-282Flow cytometry03 medical and health sciencesikzf10302 clinical medicineImmunophenotypingikzf3immunomodulatory drugsIn vivoInternal medicinemedicineImmunology and AllergyStage (cooking)t cellsMultiple myelomaOriginal ResearchLenalidomidemedicine.diagnostic_testbusiness.industrylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasePomalidomidemultiple myelomaThalidomide030104 developmental biologyOncologybiomarker trialsimmunelcsh:RC581-607business030215 immunologymedicine.drug
researchProduct

Trial Watch: Adoptively transferred cells for anticancer immunotherapy

2017

IF 7.719; International audience; Immunotherapies aimed at strengthening immune effector responses against malignant cells are growing at exponential rates. Alongside, the impressive benefits obtained by patients with advanced melanoma who received adoptively transferred tumor-infiltrating lymphocytes (TILs) have encouraged the scientific community to pursue adoptive cell transfer (ACT)-based immunotherapy. ACT involves autologous or allogenic effector lymphocytes that are generally obtained from the peripheral blood or resected tumors, expanded and activated ex vivo, and administered to lymphodepleted patients. ACT may be optionally associated with chemo- and/or immunotherapeutics, with th…

lcsh:Immunologic diseases. Allergy0301 basic medicinePD-L1Adoptive cell transferBreakthrough therapymedicine.medical_treatmentImmunology[SDV.CAN]Life Sciences [q-bio]/CancerReviewBiologycytotoxic T lymphocytelcsh:RC254-282CD19[ SDV.CAN ] Life Sciences [q-bio]/Cancer03 medical and health sciences0302 clinical medicineAntigenPD-L1PD-1medicineImmunology and AllergyCytotoxic T cellNK cellchimeric antigen receptorImmunotherapylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensChimeric antigen receptor3. Good healthimmune checkpoint blockers030104 developmental biologyOncology030220 oncology & carcinogenesisImmunologybiology.proteinlcsh:RC581-607
researchProduct

A point mutation in the Ncr1 signal peptide impairs the development of innate lymphoid cell subsets.

2018

International audience; NKp46 (CD335) is a surface receptor shared by both human and mouse natural killer (NK) cells and innate lymphoid cells (ILCs) that transduces activating signals necessary to eliminate virus-infected cells and tumors. Here, we describe a spontaneous point mutation of cysteine to arginine (C14R) in the signal peptide of the NKp46 protein in congenic Ly5.1 mice and the newly generated NCR(B6C14R) strain. Ly5.1(C14R) NK cells expressed similar levels of Ncr1 mRNA as C57BL/6, but showed impaired surface NKp46 and reduced ability to control melanoma tumors in vivo. Expression of the mutant NKp46(C14R) in 293T cells showed that NKp46 protein trafficking to the cell surface …

lcsh:Immunologic diseases. Allergy0301 basic medicineSignal peptideintracellular traffickingImmunologyCellCongenicinnate lymphoid cellsBiologymedicine.disease_causelcsh:RC254-28203 medical and health sciences0302 clinical medicinemedicineImmunology and Allergyddc:610congenic miceReceptorOriginal ResearchMutationEndoplasmic reticulumInnate lymphoid cellHEK 293 cellslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensCell biology030104 developmental biologymedicine.anatomical_structureOncologyactivation receptors[SDV.IMM]Life Sciences [q-bio]/Immunologylcsh:RC581-607030215 immunology
researchProduct

Bovine herpesvirus 4-based vector delivering the full length xCT DNA efficiently protects mice from mammary cancer metastases by targeting cancer ste…

2018

Despite marked advancements in its treatment, breast cancer is still the second leading cause of cancer death in women, due to relapses and distal metastases. Breast cancer stem cells (CSCs), are a cellular reservoir for recurrence, metastatic evolution and disease progression, making the development of novel therapeutics that target CSCs, and thereby inhibit metastases, an urgent need. We have previously demonstrated that the cystine-glutamate antiporter xCT (SLC7A11), a protein that was shown to be overexpressed in mammary CSCs and that plays a key role in the maintenance of their redox balance, self-renewal and resistance to chemotherapy, is a potential target for mammary cancer immunoth…

lcsh:Immunologic diseases. Allergy0301 basic medicinecancer stem cellmedicine.medical_treatmentImmunologylcsh:RC254-28203 medical and health sciences0302 clinical medicineBreast cancerCancer immunotherapyCancer stem cellbovine herpesvirus 4-based vector; cancer stem cell; immunotherapy; Mammary cancer; xCT; Immunology and Allergy; Immunology; OncologymedicineImmunology and Allergybovine herpesvirus 4-based vectorOriginal ResearchAntibody-dependent cell-mediated cytotoxicitybusiness.industryxCTCancerImmunotherapylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseMetastatic breast cancer030104 developmental biologyOncology030220 oncology & carcinogenesisCancer researchMammary cancerimmunotherapyStem celllcsh:RC581-607businessOncoImmunology
researchProduct

Evolution of melanoma cross-resistance to CD8⁺ T cells and MAPK inhibition in the course of BRAFi treatment

2018

The profound but frequently transient clinical responses to BRAFV600 inhibitor (BRAFi) treatment in melanoma emphasize the need for combinatorial therapies. Multiple clinical trials combining BRAFi and immunotherapy are under way to further enhance therapeutic responses. However, to which extent BRAFV600 inhibition may affect melanoma immunogenicity over time remains largely unknown. To support the development of an optimal treatment protocol, we studied the impact of prolonged BRAFi exposure on the recognition of melanoma cells by T cells in different patient models. We demonstrate that autologous CD8+ tumor-infiltrating lymphocytes (TILs) efficiently recognized short-term (3, 7 days) BRAF…

lcsh:Immunologic diseases. Allergy0301 basic medicinecd8+ t cellsmedicine.medical_treatmentT cellImmunologyMedizinlcsh:RC254-282mekresistance03 medical and health sciences0302 clinical medicineAntigenantigensmelanomaImmunology and AllergyMedicineCytotoxic T cellbusiness.industryMelanomaImmunotherapylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseTumor antigeninhibitor030104 developmental biologymedicine.anatomical_structureOncologyCSPG4030220 oncology & carcinogenesisCancer researchlcsh:RC581-607businessbrafCD8
researchProduct